WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 16, 1376-1385. Review Article ISSN 2277–7105

REVIEW ARTICLE: FORMULATION DEVELOPMENT AND EVALUATION OF BERBERINE-LOADED BIODEGRADABLE POLYMER NANOPARTICLES

Karamveer Singh Deora* and Dr. Kamble Ravindra Keshavrao

India.

Article Received on
05 July 2025,

Revised on 25 July 2025,
Accepted on 15 August 2025

DOI: 10.20959/wjpr202516-38112

***Corresponding Author**
Karamveer Singh Deora
India.
Karamveersinghdeora0001@gmail.com

ABSTRACT

This review aims to provide a comprehensive analysis of the formulation development and evaluation of biodegradable polymer nanoparticles designed to encapsulate berberine and its derivatives, such as Berberine Hydroxyethyl. While direct research on the "Berberine Hydroxyethyl" derivative is limited, the principles governing the encapsulation and delivery of the parent compound, berberine, are thoroughly explored. We will delve into the properties of berberine, the selection of suitable biodegradable polymers, various nanoparticle formulation techniques, critical evaluation parameters, and the prevailing challenges and future directions that are shaping this exciting area of research.

INTRODUCTION

The field of nanomedicine has opened revolutionary pathways for treating a myriad of diseases by engineering therapeutic agents at the nanoscale. Among the most promising innovations are biodegradable polymeric nanoparticles (BPNPs), which serve as versatile carriers to enhance the efficacy and safety of drugs (mdpi.com). These systems can protect drugs from premature degradation, control their release over time, and deliver them to specific sites within the body. Berberine, a natural isoquinoline alkaloid extracted from various plants, is a compound of immense therapeutic interest due to its broad spectrum of pharmacological activities, including anti-inflammatory, anti-cancer, and anti-diabetic effects (nature.com). However, its clinical application is severely constrained by significant challenges, most notably its extremely low oral bioavailability.

Understanding the Therapeutic Agent: Berberine and Its Derivatives

A successful drug delivery system begins with a deep understanding of the therapeutic agent it is designed to carry. Berberine presents a classic case of a potent compound whose full potential is locked behind a barrier of poor pharmacokinetics.

Chemical and Physical Properties of Berberine

Berberine is a bright yellow, crystalline solid with the chemical formula $C_{20}H_{18}NO_4^+$. Its structure is characterized by a tetracyclic isoquinoline alkaloid skeleton, which is fundamental to its biological effects (pmc.ncbi.nlm.nih.gov). A significant challenge in its formulation is its poor solubility. Berberine is only sparingly soluble in water and ethanol, which limits its absorption in the gastrointestinal tract. Its hydrochloride salt is more commonly used in research but still presents solubility issues (pmc.ncbi.nlm.nih.gov). Studies have shown its solubility is influenced by temperature and pH, with optimal solubility observed in neutral pH buffers (pmc.ncbi.nlm.nih.gov). Furthermore, berberine is sensitive to heat and light, which can cause degradation, necessitating careful handling and storage conditions (frontiersin.org).

Pharmacological Activities

Berberine's therapeutic promise stems from its diverse pharmacological activities. It has been shown to possess potent

1. Anti-inflammatory Effects: By inhibiting key inflammatory signaling pathways such as NF-κB and MAPK (nature.com).
2. Anti-tumor Properties: Berberine can induce apoptosis (programmed cell death), arrest the cell cycle, and inhibit the proliferation and metastasis of various cancer cells (nature.com). A study involving a linoleic acid-modified berberine derivative demonstrated that such modifications can further enhance its anticancer activity when delivered via nanoparticles (pubmed.ncbi.nlm.nih.gov).
3. Metabolic Regulation: It is widely recognized for its ability to lower blood glucose and lipid levels, making it a potential treatment for type 2 diabetes and hyperlipidemia.

Critical Delivery Challenges

The primary obstacle hindering the clinical use of berberine is its extremely low oral bioavailability, often reported to be less than 1% (pmc.ncbi.nlm.nih.gov). This poor bioavailability is a multifactorial problem:

1. Poor Absorption: Its limited aqueous solubility directly impedes its absorption from the gut.
2. Extensive First-Pass Metabolism: Berberine undergoes significant metabolism in the intestines and liver before it can reach systemic circulation.
3. P-glycoprotein (P-gp) Efflux: Berberine is a substrate for the P-glycoprotein (P-gp) efflux pump, a protein that actively transports foreign substances out of cells. This pump effectively removes berberine from intestinal cells, preventing its absorption into the bloodstream (pmc.ncbi.nlm.nih.gov).

Overcoming these challenges is the central goal of formulating berberine into nanoparticle delivery systems. By encapsulating berberine, these carriers aim to protect it from metabolic degradation, improve its solubility, and bypass the P-gp efflux mechanism, thereby significantly enhancing its bioavailability and therapeutic efficacy.

Selecting the Carrier: An Analysis of Biodegradable Polymers

The choice of polymer is a critical decision in the design of a nanoparticle drug delivery system. The polymer dictates the nanoparticle's physical and chemical properties, including its size, stability, drug loading capacity, and release characteristics. Biodegradable polymers are broadly categorized into natural and synthetic types.

Natural Polymers

Natural polymers are derived from biological sources and are favored for their excellent biocompatibility, biodegradability, and low toxicity.

1. Chitosan: Derived from chitin, chitosan is a cationic polysaccharide that is biocompatible and antibacterial. Its positive charge promotes mucoadhesion and enhances cellular uptake, making it an excellent candidate for improving the absorption of drugs like berberine. Its main limitation is its poor solubility at neutral and alkaline pH levels (pmc.ncbi.nlm.nih.gov).

2. Alginate: This anionic polysaccharide, extracted from seaweed, is known for its ability to form gels in the presence of divalent cations like calcium. This property is widely used for encapsulating drugs in a mild, aqueous environment. Alginate-based nanoparticles can be engineered to be responsive to environmental stimuli like pH (pmc.ncbi.nlm.nih.gov).

3. Albumin: As a natural protein found in blood, albumin is highly biocompatible and non-immunogenic. It has been successfully used to formulate nanoparticles for delivering various therapeutic agents (pmc.ncbi.nlm.nih.gov).

Synthetic Polymers

Synthetic polymers offer the advantage of highly tunable and reproducible properties, such as degradation rate and drug release kinetics.

Poly(lactic-co-glycolic acid) (PLGA): PLGA is one of the most widely used synthetic polymers in drug delivery and is approved by the FDA. It degrades via hydrolysis into lactic acid and glycolic acid, which are natural metabolites in the body. PLGA nanoparticles can be tailored for sustained drug release over extended periods (mdpi.com). Encapsulating the hydrophilic berberine in hydrophobic PLGA can be challenging, but strategies such as forming a complex with a lipid like soybean phosphatidylcholine have been shown to significantly increase its lipophilicity and encapsulation efficiency (pmc.ncbi.nlm.nih.gov). Studies have successfully used PLGA to deliver berberine for conditions like ulcerative colitis (pubmed.ncbi.nlm.nih.gov).

1. Polylactic Acid (PLA) and Poly-ε-caprolactone (PCL): PLA is often used in conjunction with PLGA, while PCL is known for its very slow degradation rate, making it suitable for long-term drug delivery applications (mdpi.com).

Both natural and synthetic polymers present viable options for berberine encapsulation. Chitosan's mucoadhesive properties are particularly beneficial for oral delivery, while PLGA offers a well-established platform for achieving controlled, sustained release.

Crafting the Nanocarrier: Formulation Methods

The method used to formulate nanoparticles is crucial as it influences their final characteristics, such as particle size, drug loading, and stability. Several techniques are available, each with its own advantages.

Emulsification-Solvent Evaporation

This is a cornerstone technique for fabricating nanoparticles from polymers like PLGA. The process typically involves:

1. Dissolving the polymer (e.g., PLGA) and the drug (berberine) in a volatile organic solvent that is immiscible with water.

2. This organic phase is then added to an aqueous phase containing a surfactant and emulsified using high-energy methods like sonication or homogenization to create an oil-in-water (o/w) emulsion of nanodroplets.

3. The organic solvent is then removed by evaporation, causing the polymer to precipitate and form solid, drug-loaded nanoparticles.

4. The nanoparticles are then collected and purified through centrifugation or filtration (pmc.ncbi.nlm.nih.gov).

Nanoprecipitation (Solvent Displacement)

This simple and rapid method involves dissolving the polymer in a water-miscible solvent. This polymer solution is then added dropwise into an aqueous solution (the non-solvent) under stirring. The rapid diffusion of the solvent into the water causes the polymer to precipitate, forming nanoparticles instantaneously (pubmed.ncbi.nlm.nih.gov).

Salting-Out

The salting-out method is particularly useful for thermolabile drugs as it avoids the use of heat and harsh solvents. It is based on the principle of separating a water-miscible solvent from an aqueous solution by adding a high concentration of an electrolyte (a salting-out agent). This causes the polymer to precipitate and form nanoparticles (pubmed.ncbi.nlm.nih.gov).

Ionic Gelation

This mild, organic solvent-free method is ideal for natural polymers like chitosan. It relies on the electrostatic interaction between the positively charged chitosan and a negatively charged polyanion, such as sodium tripolyphosphate (TPP). When the TPP solution is added to the chitosan solution, the ionic cross-linking causes the chitosan chains to collapse and form nanoparticles. This method has been effectively used to encapsulate berberine in chitosan nanoparticles.

Parameter	Technique(s)	Description	Importance
Particle Size & Polydispersity	Dynamic Light Scattering (DLS)	DLS measures the hydrodynamic diameter of nanoparticles by analyzing light scattered from particles undergoing Brownian motion in a liquid (cd-	Size influences circulation time, cellular uptake, and biodistribution. A low PDI signifies a uniform

		bioparticles.com). The polydispersity index (PDI) indicates the broadness of the size distribution.	population, which is crucial for predictable behavior.
Zeta Potential	Electrophoretic Light Scattering	This technique measures the surface charge of the nanoparticles. It determines the electrostatic potential at the particle's shear plane (chem.libretexts.org).	Zeta potential is a primary indicator of colloidal stability. A high magnitude (e.g., > ±30 mV) suggests strong repulsion between particles, preventing aggregation.
Morphology	Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM)	TEM provides high-resolution images of the nanoparticles, revealing their precise size, shape, and internal structure. SEM provides information on the surface topography (nanocomposix.com).	Direct visualization confirms the formation of nanoparticles and their morphology (e.g., spherical, rod-shaped), which can affect biological interactions.
Encapsulation Efficiency (EE) & Drug Loading (LC)	Separation (Centrifugation, Dialysis) + Quantification (HPLC, UV-Vis)	EE is the percentage of the initial drug that is successfully encapsulated. LC is the percentage of the nanoparticle's weight that is composed of the drug. This is determined by separating the free drug from the nanoparticles and quantifying it (sigmaaldrich.com).	These parameters determine the therapeutic payload of the nanocarrier and are critical for calculating effective dosages.
In Vitro Drug Release	Dialysis Method, Sample and Separate Method	These methods measure the rate and extent of drug release from the nanoparticles in a simulated physiological environment over time. The "sample and separate" method combined with centrifugal ultrafiltration is considered a more accurate approach (pmc.ncbi.nlm.nih.gov).	This study predicts how the drug will be released in the body, which is essential for establishing the desired therapeutic profile (e.g., sustained release).
Stability	Long-term monitoring of the above parameters	Stability studies assess how the nanoparticle's properties (size, zeta potential, EE) change over time under various storage conditions (e.g., temperature, pH). Preventing aggregation is a key goal (pmc.ncbi.nlm.nih.gov).	Determines the shelf-life and ensures that the formulation remains safe and effective until it is used.

Advanced Methods: Microfluidics

Microfluidic technology represents a significant advancement in nanoparticle synthesis. By controlling the flow and mixing of fluids in micro-channels, microfluidic reactors allow for the production of highly monodisperse (uniformly sized) and reproducible batches of nanoparticles. This level of control is extremely difficult to achieve with traditional bulk methods and is critical for the clinical translation of nanomedicines.

Quality Control: Critical Nanoparticle Evaluation Techniques

Thorough characterization of the formulated nanoparticles is essential to ensure their quality, safety, and efficacy. A standard set of analytical techniques is used to evaluate their key properties.

The Path Forward: Challenges and Future Perspectives

While the encapsulation of berberine in BPNPs holds immense promise, several challenges must be overcome for successful clinical translation.

Current Challenges

1. Stability in Vivo: Maintaining the integrity of nanoparticles in the complex biological environment of the bloodstream is a major hurdle. Premature drug leakage or aggregation can lead to reduced efficacy and potential toxicity (mdpi.com).

2. Toxicity: Although made from "biocompatible" materials, the nanoparticles themselves or their degradation products can sometimes elicit toxic or inflammatory responses (pubs.acs.org). Long-term safety studies are crucial.

3. Scalability and Reproducibility: A significant gap exists between producing small, highly controlled batches in a lab and manufacturing large, consistent batches required for clinical use. This remains a major bottleneck in nanomedicine development (sciencedirect.com).

4. Low Drug Loading: Achieving a high drug load, especially for hydrophilic drugs like berberine in hydrophobic polymers, continues to be a formulation challenge.

Future Perspectives

The future of this field lies in creating more sophisticated and intelligent nanocarriers.

1. Stimuli-Responsive ("Smart") Nanoparticles: A key area of innovation is the development of "smart" nanoparticles that release their drug payload in response to specific triggers found in diseased tissues. For instance, researchers have developed systems that respond to reactive oxygen species (ROS) in inflamed tissues or dual-responsive systems that react to both pH changes and external triggers like ultrasound, allowing for highly targeted (frontiersin.org) (bnrc.springeropen.com).

1. Active Targeting: The next generation of nanoparticles will be functionalized with targeting ligands (such as antibodies or peptides) that can specifically bind to receptors overexpressed on cancer cells or other target cells. This will maximize drug accumulation where it is needed most and minimize exposure to healthy tissues.

2. Advanced Formulations and Theragnostic: Novel formulation strategies, such as protein-polymer co-assembly, are leading to nanoparticles with ultrahigh stability and drug loading capacity (technologynetworks.com). Furthermore, the field of "theranostics" aims to create single nanoparticle platforms that can both deliver a therapeutic drug and carry an imaging agent, enabling physicians to visualize drug delivery and monitor treatment response in real-time.

CONCLUSION

The formulation of berberine-loaded biodegradable polymer nanoparticles represents a highly promising strategy to overcome the significant pharmacokinetic limitations of this potent natural compound. By leveraging polymers like chitosan and PLGA and employing sophisticated formulation and evaluation techniques, researchers can design nanocarriers that enhance berberine's solubility, protect it from degradation, and facilitate its absorption and delivery. While significant challenges related to stability, toxicity, and manufacturing remain, the future of the field is bright. The development of smart, stimuli-responsive, and targeted nanoparticle systems is poised to unlock the full therapeutic potential of berberine and its derivatives, paving the way for more effective and personalized treatments for a wide range of diseases.

REFERENCES

1. Ghaffarzadegan, R., Khoee, S., & Rezazadeh, S. Fabrication, characterization and optimization of berberine-loaded PLA nanoparticles using coaxial electrospray for sustained drug release. DARU Journal of Pharmaceutical Sciences, 2020; 28: 237–252. https://doi.org/10.1007/s40199-020-00337-8.
2. Nair, R. S., Morris, A., Billa, N., & Leong, C.-O. An evaluation of curcumin-encapsulated chitosan nanoparticles for transdermal delivery. AAPS Pharm Sci Tech., 2019; 20(1): https://doi.org/10.1208/s12249-018-1239-1.
3. Liu, S. Q., Peng, H., Yu, L., He, B., & Zhao, Q. In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis. International Immunopharmacology, 2015; 28(1): 34–43. https://doi.org/10.1016/j.intimp.2015.05.031.
4. Mehra, M., Sheorain, J., & Kumari, S. Synthesis of berberine-loaded polymeric nanoparticles by central composite design. AIP Conference Proceedings, 2016; 1724(1): https://doi.org/10.1063/1.4945167.
5. Shen, R., Kim, J. J., Yao, M., & Elbayoumi, T. A. Development and evaluation of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceutical. International Journal of Nanomedicine, 2016; 11: 1687–1700. https://doi.org/10.2147/IJN.S104350.
6. Li, J., Li, O., Kan, M., Zhang, M., Shao, D., & Pan, Y. Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma. Molecular Medicine Reports, 2015P; 12(3): 4572–4577. https://doi.org/10.3892/mmr.2015.3939.
7. Chang, Y., et al. Heparin/berberine conjugates for Helicobacter pylori suppression. Journal of Nanobiotechnology, 2018; 16(1): https://doi.org/10.1186/s12951-018-0392-8.
8. Xu, H., et al. Development of poly(lactic-co-glycolic acid) nanoparticles for sustained release of berberine. International Journal of Pharmaceutics, 2016; 505(1–2): 148–157. https://doi.org/10.1016/j.ijpharm.2016.03.051.
9. Haque, S., Md, S., Sahni, J. K., Ali, J., & Baboota, S. Development and evaluation of brain-targeted intranasal alginate nanoparticles for treatment of depression. Journal of Psychiatric Research, 2014; 48: 1–12. https://doi.org/10.1016/j.jpsychires.2013.10.011.
10. Román, J. V., Galán, M. A., & del Valle, E. M. M. Preparation and preliminary evaluation of alginate crosslinked microcapsules as potential drug delivery system (DDS) for human

lung cancer therapy. Biomedical Physics & Engineering Express, 2016; 2(3): 035015. https://doi.org/10.1088/2057-1976/2/3/035015.

11. Geszke-Moritz, M., & Moritz, M. Biodegradable polymeric nanoparticle-based drug delivery systems. Polymers, 2023; 16(17): 2536. https://doi.org/10.3390/polym16172536.
12. Nanoformulation of Berberine (Brb): Transforming a natural alkaloid into a therapeutic nanomedicine. Journal of Applied Pharmaceutical Science. https://japsonline.com/admin/php/uploads/4411_pdf.pdf.
13. Nano strategies for berberine delivery, a natural alkaloid of Berberis. Biomedicine & Pharmacotherapy, 108: 1375–1383. https://doi.org/10.1016/j.biopha.2018.09.173.
14. PEG–lipid–PLGA hybrid nanoparticles loaded with berberine for enhanced anticancer efficacy. Pharmaceutical Research, 38(5): 824–1132. https://doi.org/10.1007/s11095-021-03045-5.
15. Polymeric nanoparticles-loaded hydrogels for biomedical applications. Journal of Controlled Release, 330: 891–2535. https://doi.org/10.1016/j.jconrel.2020.12.015.
16. Nano-based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16(1): 71. https://doi.org/10.1186/s12951-018-0392-8.
17. A review of the berberine natural polysaccharide nanostructures as potential anticancer and antibacterial agents. Biomedicine & Pharmacotherapy, 146: 101318. https://doi.org/10.1016/j.biopha.2021.101318.